DOTA-Conjugated JM#21 Derivative 7 (compound Ligand-7) is a CXCR4-targeting peptide derivative conjugated with DOTA, suitable for producing radioligands. Radiolabeled with 177Lu, this compound, referred to as 177Lu-DOTA, demonstrates superior CXCR4 tumor targeting capabilities. In vitro biodistribution studies of 177Lu-DOTA indicate minimal uptake in non-target organs, with the exception of the kidneys.